MXPA06009094A - Formulaciones de liberacion controlada. - Google Patents

Formulaciones de liberacion controlada.

Info

Publication number
MXPA06009094A
MXPA06009094A MXPA06009094A MXPA06009094A MXPA06009094A MX PA06009094 A MXPA06009094 A MX PA06009094A MX PA06009094 A MXPA06009094 A MX PA06009094A MX PA06009094 A MXPA06009094 A MX PA06009094A MX PA06009094 A MXPA06009094 A MX PA06009094A
Authority
MX
Mexico
Prior art keywords
morphine
further characterized
composition according
composition
chitosan
Prior art date
Application number
MXPA06009094A
Other languages
English (en)
Spanish (es)
Inventor
Michael Moshman
Fred Mermelstein
Original Assignee
Innovative Drug Delivery Syste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Drug Delivery Syste filed Critical Innovative Drug Delivery Syste
Publication of MXPA06009094A publication Critical patent/MXPA06009094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA06009094A 2004-02-10 2005-02-09 Formulaciones de liberacion controlada. MXPA06009094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/776,333 US20050175679A1 (en) 2004-02-10 2004-02-10 Controlled release formulations
PCT/US2005/004163 WO2005077346A1 (en) 2004-02-10 2005-02-09 Controlled release formulations

Publications (1)

Publication Number Publication Date
MXPA06009094A true MXPA06009094A (es) 2007-02-02

Family

ID=34827359

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06009094A MXPA06009094A (es) 2004-02-10 2005-02-09 Formulaciones de liberacion controlada.

Country Status (10)

Country Link
US (2) US20050175679A1 (https=)
EP (1) EP1720532A1 (https=)
JP (1) JP2007522223A (https=)
KR (1) KR20060135769A (https=)
AU (1) AU2005212355B2 (https=)
BR (1) BRPI0506630A (https=)
CA (1) CA2555882A1 (https=)
IL (1) IL177328A0 (https=)
MX (1) MXPA06009094A (https=)
WO (1) WO2005077346A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083984A1 (en) 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
KR100766820B1 (ko) 2006-01-23 2007-10-17 광주과학기술원 단백질 또는 펩타이드의 경점막 운반 시스템
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
JP5258315B2 (ja) * 2007-05-25 2013-08-07 ロート製薬株式会社 フルニソリド含有粘膜適用組成物
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
BR112014004418A8 (pt) * 2011-08-25 2018-01-23 Evoke Pharma Inc método de tratamento de sintomas associados à gastroparesia feminina
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
JP7217071B2 (ja) * 2019-09-30 2023-02-02 エルジー・ケム・リミテッド 高吸水性樹脂およびその製造方法
EP4230206A1 (en) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5508282C1 (en) * 1993-05-17 2001-01-23 Tulin Silver Jeffrey Composition and method for treating acute or chronic rhinosinusitis
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JP4137179B2 (ja) * 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9605867D0 (en) * 1996-03-20 1996-05-22 Svedman Paul Transdermal device
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
HRP20010926A2 (en) * 1999-06-16 2003-04-30 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale

Also Published As

Publication number Publication date
AU2005212355B2 (en) 2010-06-17
KR20060135769A (ko) 2006-12-29
JP2007522223A (ja) 2007-08-09
IL177328A0 (en) 2006-12-10
CA2555882A1 (en) 2005-08-25
US20050175679A1 (en) 2005-08-11
EP1720532A1 (en) 2006-11-15
AU2005212355A1 (en) 2005-08-25
US20080221144A1 (en) 2008-09-11
BRPI0506630A (pt) 2007-05-08
WO2005077346A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EP2744572B1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
CA2460140C (en) Compositions for treatment of common cold
AU775112B2 (en) Compositions and methods comprising morphine gluconate
US20080221144A1 (en) Controlled Release Formulations
MX2012005456A (es) Uso de betanecol para el tratamiento de xerostomia.
AU2004268602A1 (en) Intranasal opioid compositions
US12458625B2 (en) Methods and compositions for soft anticholinergic esters
GB2481407A (en) A rapid onset liquid midazolam composition for buccal administration
US20240216360A1 (en) Drug products for intranasal administration and uses thereof
EP3927321B1 (en) Naloxone formulations for sublingual and/or buccal administration
US20240408004A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
EP3582765B1 (en) Midodrine hydrochloride oral solution and uses thereof
CA3124202A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
CN113712920B (zh) 一种盐酸氨溴索口腔喷雾剂及制备方法
WO2017044411A1 (en) Methods and compositions for soft anticholinergic zwitterions
CA2998357C (en) Compositions comprising a soft anticholinergic ester
HK1255558B (en) Methods and compositions for soft anticholinergic esters
HK1113086A1 (en) Pharmaceutical formulation of apomorphine for buccal administration
HK1113086B (en) Pharmaceutical formulation of apomorphine for buccal administration
HK1198958B (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Legal Events

Date Code Title Description
FG Grant or registration